Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Further strengthens BaseLaunch's global pharma industry partnerships
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
Establishing Asymchem’s first manufacturing footprint in Europe
_256_384.jpg)
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
Subscribe To Our Newsletter & Stay Updated
